Up to 100% in a month, and now? D-Wave, Palantir, and Hotstock PanGenomic Health

PanGenomic Health: 100% price gain not enough?

We pointed out a few weeks ago that the shares of PanGenomic Health could be the high flyer of the second half of the year. And now they have taken off. The share price has roughly doubled in the past four weeks. The market capitalization remains below CAD 30 million. In terms of potential, this is anything but too high.

With apps and e-commerce for personalized alternative medicine and nutritional supplements such as immune, sports, and beauty supplements in the US, the Company is entering a billion-dollar market in the second half of the year. The Company's vision: a smart, AI-enabled platform built around the Nara app, capable of identifying what your body truly needs – and delivering it directly.

PanGenomic CEO Maryam Marissen commented: "Consumers and their healthcare providers are faced with the challenge of understanding which alternative health products are right for a person's holistic health, and we believe our NaraCare.AI platform can become a trusted source for consumers and healthcare providers across North America."

The Nara e-commerce shopping platform is expected to go live during the current third quarter. The NaraCare.AI platform is then expected to delight customers starting in the fourth quarter of 2025. The NaraCare.AI platform was developed using leading AI models and is designed to present personalized alternative health treatments, providing users with evidence-based information about benefits, dosages, potential side effects, and interactions with other medications.

If PanGenomic succeeds in capturing even a small market share, the stock could more than double again.

D-Wave: Now conquering Asia

While PanGenomic is still in its infancy, D-Wave Quantum's stock has gained over 1,000% in just a few months. The valuation is high, but there is also positive news: Most recently, strong growth was reported for the Asia-Pacific region. Bookings for the Company's proprietary quantum annealing technology rose by 83% within a year. To attract more customers, the first user conference will take place in Tokyo on September 17, 2025. The focus there will be on practical applications. Recent projects include a pilot project by Japan Tobacco's pharmaceutical division for AI-supported drug development and a collaboration with telecommunications giant NTT DOCOMO, which has been able to reduce the load on its mobile network during peak times through quantum optimization. In addition, a partnership with Yonsei University and the Incheon metropolitan area is advancing research and education in quantum computing.

Financially, D-Wave reported a higher-than-expected loss per share in the second quarter of 2025, but significantly exceeded revenue forecasts. The strong results, combined with a 120% year-on-year increase in revenue and a gross margin of 82%, prompted analysts such as Piper Sandler and Benchmark to raise their price targets and buy recommendations. Analysts continue to highlight D-Wave's technological leadership and a rapidly expanding customer base.

Palantir: Extreme valuation

There is little debate about whether Palantir shares are inexpensive. After the Company reported quarterly revenue of USD 1 billion for the first time, the stock shot up to over USD 180, marking a gain of more than 140% in 2025 alone. This values the software company at more than USD 430 billion.

However, this is not stopping analysts from continuing to recommend the stock as a "Buy". Wedbush is among the Palantir bulls. Analysts recently raised their price target from USD 160 to USD 200 and confirmed their "Outperform" rating. The update was prompted by the signing of a strategically important framework agreement with the US Army over the next 10 years, with a volume of up to USD 10 billion. Wedbush believes that Palantir will benefit significantly from the expected increase in government investment in AI.

Piper Sandler sees a unique growth and margin structure at Palantir. In 2032, the Company could achieve a revenue run rate of USD 24 billion. The analysts rate the stock as "Overweight." However, with a price target of USD 170, they are already lagging behind the current price.

However, alarm bells are ringing at well-known short seller Citron Research. Analysts believe that Palantir's P/E ratio of 242 and P/S ratio of 137 are significantly too high. Even with strong revenue and profit growth, there is a risk of significant price declines.

PanGenomic's stock has surged, and if the Company succeeds in capturing even a small market share, the stock could more than double again. D-Wave remains the only pure-play in the quantum sector. The valuation is high, but so far, the Company has delivered accordingly in terms of operations. Palantir, meanwhile, is increasingly becoming something of a "cult stock" - reminiscent of Tesla. Either you believe in it or you do not – valuation does not matter. Short sellers need strong nerves here.